- Conditions
- Macular Degeneration
- Interventions
- Retisert Implant
- Drug
- Lead sponsor
- Control Delivery Systems
- Industry
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Watertown, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–130
of 130
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age Related Macular Degeneration
- Interventions
- NeoVista Ophthalmic System
- Device
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Honolulu, Hawaii
- Conditions
- Retinal Pigment Epithelial Detachment
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Clement K. Chan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Michael Abramoff
- Other
- Eligibility
- 45 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Pathologic Neovascularization, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 67
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 59 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Macular Degeneration
- Interventions
- Angiography, Laser Treatment
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more